April 2014

The CIBMTR collaboration is now in its tenth year and to celebrate we have a new look that is a better representation of who we are.
  
The two intersecting circles of the new logo represent the spirit of collaboration that characterizes our work. Collaboration with the scientific community, clinicians, payers and patients, and within our organization. Collaboration between the NMDP and MCW to operate the CIBMTR's Coordinating Center. Similar to our previous logo, the figure points upward, reflecting our continued commitment to facilitating forward progress in the field of hematopoietic cell transplantation (HCT) and cellular therapy.

 

The new CIBMTR logo was formally introduced at the 2014 BMT Tandem Meetings. Since then, we have begun the work to transition our materials and our website over to the new color scheme and logo.

 

Sincerely,

CIBMTR Data Operations

 

CIBMTR® is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin.

 

QUICK LINKS
MANUAL UPDATES
2016: (PCD) Pre-HCT Data
2006: HCT Infusion
2400: Pre-TED
2450: Post-TED
CRP/DM in San Diego

 

Would you like to present your idea at 2015 CRP/DM Meetings?

Have you developed a helpful strategy for data collection and reporting that we'd like to hear about?  To be a panelist in Oral Abstracts during our meetings next year, a written abstract entry will be due this Fall. M ore d etails on abstract entry will be in an upcoming newsletter. Any ideas?
BUSULFAN DOSING ON Pre-TED FORM 2400

This is a reminder for centers that utilize Area Under the Curve (AUC) dosing for Busulfan. With the release of the revised Pre-TED Form 2400 R4 (released last October), changes were made to the Busulfan unit of measure options in the preparative regimen section. Centers can now indicate the prescribed dose unit of measure as "target total AUC", rather than converting to mg/kg. The Instructions in the Pre-TED Form 2400 Manual regarding AUC dosing were also updated to reflect this change (page 33), and the instructions regarding Busulfan in the memorandum sent in August 2013 titled "Reporting Preparative Regimen Doses Correctly to the CIBMTR", can be disregarded.

 

QUIZ YOURSELF

 

How well can you answer these questions on "Other, specify" fields?  Scroll down to see the correct answers at the end of this newsletter.

  

(1) If the patient's drug is not included in the common drug list, which drug name should you enter in the 'Other, specify' field?

A.  Generic name

B.  Brand name

C.  Use the local terminology

D.  Any of the above 

 

 

(2) Which of these answers is the correct way to report Pulmonary Function?

A.  Check the box for: 'DLCO <50%'

B.  Other, specify: "Decreased DLCO"
C.  Other, specify: "DLCO 53%"
D.  None of the above are correct
(3) If the patient had a splenectomy to treat their primary disease, where should this be reported?  

A.  Disease specific form

B.  Other endocrine, specify

C.  Other GI, specify

D.  This is not clinically significant to  report.

 

 

(4) If a patient received a hysterectomy for fibroids, should this be reported in the 'Other, specify' field?
A.  Yes, as - Hysterectomy
B.  Yes, as - Fibroids
C.  No, this is not clinically significant to report
D.  Yes, as - Disease, other
  

(5) If a patient received a hysterectomy for endometrial cancer, where does that get reported?

A.  as - 'hysterectomy' under genitourinary, other

B.  as - 'hysterectomy' in other, other

C.  Check box 'genitourinary cancer' in hx malignancy

D.  This is not clinically significant to report.

 

(6) Patient had a history of Hepatitis 10 years ago. Where should this be reported?

A.  TED (Sorror)

B.  Disease form

C.  This is not clinically significant to report.

D.  Other, specify field

 

 

(7) Entering information in the "Other,specify" field is just as good as putting it somewhere else.  At least this way CIBMTR has the information somewhere.

A.  True

B.  False

(8) The "Other, specify" fields should only be used if the data answer was not one of the options in a specific question, and the data answer is clinically significant to the transplant.

A.  True

B.  False

 

 

 

PAPER FORMS AND ERROR CORRECTIONS
We know that many centers use the paper forms for a variety of reasons, such as gathering data prior to entry into FormsNet. The (PDF) forms on our website under Data Collection Forms are the most current and should always be the ones used for data collection or for training new staff on how to complete forms. 
 
The Retired Forms are only available in case you need to make a correction to a previous version of the form. In that case, the version of the error correction form must match the version of the form that was originally submitted (for example: if a 2400 R2 was submitted and a change is needed, then the 2400 R2 error correction form must be used). 
  • With the release of FormsNet3, all corrections to data submitted using FormsNet2 need to be sent via Paper Error Corrections, as well as all Legacy Data (submitted prior to FormsNet2). 
  • Data entered into FormsNet3 (since 12/4/12) can be corrected online.
  • Error Correction forms for FormsNet2 versions of the forms are available on Retired Forms page of CIBMTR's website.

 

Please make sure to go to the Retired Forms page for all FormsNet2 documents, the question number and sometimes entire questions can be different depending on the version of the form used.  

 

Instructions for completing Paper Error Correction Forms

 

 

  

 

 

 

 

 

 

Question:  

When reviewing forms to complete in FormsNet3, I noticed that both TED forms and CRF forms were due for the same visit.  Is that right?   

 

Answer:

No, both TED and CRF forms should never be due for the same time point (ex: a 1 year 2450, a 1 year 2200, and a 1 year disease insert). Please contact your CRC and ask that the forms due list in FormsNet3 be corrected. Don't submit any forms until the forms due list is corrected, as this can cause many issues in the future. 

 

Send your questions into CIBMTRTraining@nmdp.org . The answer may be in a future newsletter.
CIBMTR Training   
Thank you to the contributors for this month's newsletter:
Roberta King, Marie Matlack, Alisha Mussetter, Emilie Love, Sue Logan, Jenni Bloomquist, and Lori Colt.

Quiz Answers: 1-A; 2-A; 3-A; 4-C; 5-C; 6-C; 7-B; 8-A